Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement

Rani Therapeutics Holdings

13/08/2026 21:18

Overview
US oral biologics developer's Q2 contract revenue rose to $1.7 mln from zero last year
Q2 net loss narrowed to $8.4 mln from $11.2 mln a year earlier
Company completed $20 mln registered direct offering and expanded obesity pipeline via PegBio collaboration

Outlook
Rani expects additional RT-114 Phase 1a data by end of 2026
Company plans to initiate Phase 1b RT-114 obesity study by end of 2026, data in 2027
Rani expects cash and equivalents to fund operations at least through 2027

Result Drivers
CLINICAL PROGRESS - Positive initial Phase 1a data for RT-114 showed oral bioavailability exceeding subcutaneous dosing, with continued advancement in the clinic
COLLABORATION REVENUE - Increase in contract revenue was primarily due to the collaboration and license agreement with Chugai
PIPELINE EXPANSION - Obesity pipeline expanded through new research and development collaboration with PegBio

Company press release: ID:nGNX5WQCML

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$8.42 mln
 
Q2 Operating Expenses
 
$10.54 mln
 
Q2 Operating Income
 
-$8.83 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $7.00, about 771.9% above its August 12 closing price of $0.80

Reuters Recommended Reads
Aug 12 - Altimmune posts smaller-than-expected Q2 net loss per share 
Aug 10 - Eli Lilly's weight-loss pill secures first European nod in Britain
Aug 10 - Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)